Fortis Inc. stock rises Friday, outperforms market
Fortis Inc. closed 2.6% below its 52-week high of C$64.39, which the company reached on February 14th.
Coeptis Therapeutics’ NexGenAI partners with Arketyp Valu
Coeptis announced a strategic partnership with Coeptis’ NexGenAI Affiliates Network and Arketyp Valu, a developer within the open-source Verus ...
Fortis Inc. stock rises Wednesday, outperforms market
Fortis Inc. closed 2.9% short of its 52-week high of C$64.39, which the company achieved on February 14th.
Fortis price target raised to C$62.50 from C$61 at Raymond James
Raymond James analyst Theo Genzebu raised the firm’s price target on Fortis (FTS) to C$62.50 from C$61 and keeps a Market Perform rating on the ...
archive14d
A Handbook of Therapeutics
An illustration of a magnifying glass. An illustration of a magnifying glass.
Mena FN17d
Metastatic Castration-Resistant Prostate Cancer Market To See Unprecedented Growth By 2034 Delveinsight
Leading companies like Novartis, Merck, and Bristol Myers Squibb are spearheading advancements, redefining patient treatment possibilities. < ...
BayStreet17d
Medicenna Therapeutics Corp
Copyright 1998 - 2025 Baystreet.ca Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes ...
Wall Street Journal22d
Applied Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...